EUVIMEDEUVIMED entdecken
Crossref

G9a epigenetically suppresses CXCL10 expression and inhibits anti‐tumor immunity in hepatocellular carcinoma

Xinxin Chai, Jingzhou Chen, Yuanyuan Zhao, Weiwei Chu, Jianuo Zhou, Yurong Zhao, Zhen Hu, Jiayi Zhu, Yi Zhu, Zhengping Xu iD, Jinghao Sheng iD

International Journal of Cancer · 2026

DOI: 10.1002/ijc.70284 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Xinxin Chai und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Environmental Medicine and Department of General Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, C…. Hauptthemen laut MEDLINE: Chemokine CXCL10, Carcinoma, Hepatocellular, Liver Neoplasms, Histone-Lysine N-Methyltransferase. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Zhejiang Provincial Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The immunosuppressive tumor microenvironment, characterized by limited immune cell infiltration, represents a major challenge for effective immunotherapy in hepatocellular carcinoma (HCC). Epigenetic dysregulation has emerged as a critical mechanism underlying tumorigenesis and progression; however, the specific epigenetic mechanisms governing immune infiltration remain poorly understood. Here, we investigated the role of G9a, a histone methyltransferase catalyzing H3K9 methylation, in modulating anti‐tumor immunity in HCC. Bioinformatic analysis of human HCC datasets revealed a significant inverse correlation between G9a expression and T cell infiltration. Genetic ablation of G9a in hepatoma cells markedly enhanced CD8 + T cell recruitment and activation in immunocompetent mouse models. Through RNA sequencing and functional validation, we identified CXCL10 as the key chemokine directly repressed by G9a. Mechanistically, G9a mediates H3K9 dimethylation at the CXCL10 promoter, and G9a deletion or inhibition significantly reduced this repressive mark, resulting in increased CXCL10 expression and secretion. Importantly, neutralization of CXCL10 abolished G9a inhibition‐induced enhancement of CD8 + T cell migration. In preclinical models, pharmacological inhibition of G9a with UNC0642 not only suppressed tumor growth by promoting T cell infiltration but also synergized with anti‐PD1 therapy to achieve superior therapeutic efficacy. These findings establish G9a as an epigenetic regulator of anti‐tumor immunity in HCC and provide evidence for combining G9a inhibitors with immune checkpoint blockade to improve outcomes for HCC patients who are receiving immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chemokine CXCL10Carcinoma, HepatocellularLiver NeoplasmsHistone-Lysine N-MethyltransferaseHistocompatibility AntigensAnimalsHumansMiceEpigenesis, GeneticTumor MicroenvironmentCD8-Positive T-LymphocytesCell Line, TumorGene Expression Regulation, NeoplasticMice, Inbred C57BLLymphocytes, Tumor-Infiltrating

Stichwörter der Autor:innen

CD8+ T cellCXCL10G9aepigeneticshepatocellular carcinoma

Substanzen

Chemokine CXCL10Histone-Lysine N-MethyltransferaseEHMT2 protein, humanCXCL10 protein, humanHistocompatibility AntigensG9a protein, mouse

Autor:innen und Institutionen

  • Institute of Environmental Medicine and Department of General Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Liangzhu Laboratory, Zhejiang University, Hangzhou, China.
  • Cancer Center, Zhejiang University, Hangzhou, China.
  • Department of Clinical Pharmacy, The First Affiliated Hospital of Xinxiang Medical University, Weihui, China.
  • Clinical Pharmacy, Henan Province Key Subjects of Medicine, The First Affiliated Hospital of Xinxiang Medical University, Weihui, China.

ORCID-Profile: Zhengping Xu, Jinghao Sheng

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Zhejiang Provincial Natural Science Foundation of China
  • Leading Innovation and Entrepreneur Team of Hangzhou
  • Fundamental Research Funds for the Provincial Universities of Zhejiang

Zitieren

APA

Chai, X., Chen, J., Zhao, Y., Chu, W., Zhou, J., Zhao, Y., Hu, Z., Zhu, J., Zhu, Y., Xu, Z., & Sheng, J. (2026). G9a epigenetically suppresses CXCL10 expression and inhibits anti‐tumor immunity in hepatocellular carcinoma. International Journal of Cancer. https://doi.org/10.1002/ijc.70284

Vancouver

Chai X, Chen J, Zhao Y, Chu W, Zhou J, Zhao Y, et al. G9a epigenetically suppresses CXCL10 expression and inhibits anti‐tumor immunity in hepatocellular carcinoma. International Journal of Cancer. 2026. doi:10.1002/ijc.70284

BibTeX
@article{Chai2026,
  author = {Chai, Xinxin and Chen, Jingzhou and Zhao, Yuanyuan and Chu, Weiwei and Zhou, Jianuo and Zhao, Yurong and Hu, Zhen and Zhu, Jiayi and Zhu, Yi and Xu, Zhengping and Sheng, Jinghao},
  title = {G9a epigenetically suppresses CXCL10 expression and inhibits anti‐tumor immunity in hepatocellular carcinoma},
  journal = {International Journal of Cancer},
  year = {2026},
  doi = {10.1002/ijc.70284}
}
Kostenlos starten →